Pfizer, Eli Lilly, Janssen and Regeneron are advancing a promising class of analgesic drugs, hoping to put concerns around autonomic dysfunction and joint destruction behind them.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Mullard, A. Drug developers reboot anti-NGF pain programmes. Nat Rev Drug Discov 14, 297â298 (2015). https://doi.org/10.1038/nrd4612
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4612
This article is cited by
-
Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review
BioDrugs (2021)
-
Combining Human and Rodent Genetics to Identify New Analgesics
Neuroscience Bulletin (2018)
-
Pharmacological Treatment of Pain in Osteoarthritis: A Descriptive Review
Current Rheumatology Reports (2018)
-
Outlook for NGF inhibitor painkiller class brightens
Nature Biotechnology (2016)